Bethkis
Bethkis is an aminoglycoside antibacterial inhalation solution indicated for the management of active lung infections caused by Pseudomonas aeruginosa bacteria in cystic fibrosis patients aged 6 years and older.
Dosage by Body Weight
The recommended dosage for adults and pediatric patients 6 years of age and older is one single-use ampule (300 mg/4 mL) administered twice daily by oral inhalation in alternating cycles of 28 days on drug, followed by 28 days off drug. Dosage is not calculated by body weight and is not approved for patients under 6 years of age.
- Body Weight
- Below 5 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy not established in pediatric patients under 6 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy not established in pediatric patients under 6 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy not established in pediatric patients under 6 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy not established in pediatric patients under 6 years of age.
- Body Weight
- 16-20 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Safety and efficacy not established in pediatric patients under 6 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not established | Not recommended | Safety and efficacy not established in pediatric patients under 6 years of age. |
| 5-7 kg | Not established | Not recommended | Safety and efficacy not established in pediatric patients under 6 years of age. |
| 8-10 kg | Not established | Not recommended | Safety and efficacy not established in pediatric patients under 6 years of age. |
| 11-15 kg | Not established | Not recommended | Safety and efficacy not established in pediatric patients under 6 years of age. |
| 16-20 kg | Not established | Not recommended | Safety and efficacy not established in pediatric patients under 6 years of age. |
Formulation
Purpose
Management of cystic fibrosis patients with Pseudomonas aeruginosa infections
Generic Name
Tobramycin (inhalation)Scheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.